Verve Therapeutics Inc [NASDAQ: VERV] plunged by -$0.03 during the normal trading session on while it closed the day at $5.16.
Verve Therapeutics Inc stock has also loss -9.95% of its value over the past 7 days. However, VERV stock has declined by -31.38% in the 3 months of the year. Over the past six months meanwhile, it has lost -10.88% and lost -8.51% year-on date.
The market cap for VERV stock reached $459.98 million, with 88.76 million shares outstanding and 66.38 million shares in the current float. Compared to the average trading volume of 2.76M shares, VERV reached a trading volume of 1807435 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Verve Therapeutics Inc [VERV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VERV shares is $23.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VERV stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Verve Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 15, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on April 08, 2024, representing the official price target for Verve Therapeutics Inc stock. Previously, the target price had yet another raise to $29, while Canaccord Genuity analysts kept a Buy rating on VERV stock.
The Average True Range (ATR) for Verve Therapeutics Inc is set at 0.54, with the Price to Sales ratio for VERV stock in the period of the last 12 months amounting to 14.23. The Price to Book ratio for the last quarter was 0.93, with the Price to Cash per share for the same quarter was set at 5.88.
VERV stock trade performance evaluation
Verve Therapeutics Inc [VERV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.95. With this latest performance, VERV shares gained by 34.20% in over the last four-week period, additionally sinking by -10.88% over the last 6 months – not to mention a drop of -14.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VERV stock in for the last two-week period is set at 50.67, with the RSI for the last a single of trading hit 50.73, and the three-weeks RSI is set at 49.32 for Verve Therapeutics Inc [VERV]. The present Moving Average for the last 50 days of trading for this stock 5.32, while it was recorded at 5.40 for the last single week of trading, and 5.85 for the last 200 days.
Verve Therapeutics Inc [VERV]: An insightful look at the core fundamentals
Verve Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.65 and a Current Ratio set at 12.65.
Earnings per share (EPS) analysis for Verve Therapeutics Inc [VERV] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VERV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Verve Therapeutics Inc go to 6.26%.
Verve Therapeutics Inc [VERV]: Institutional Ownership
The top three institutional holders of VERV stocks are: ALPHABET INC. with ownership of 12.35 million shares, which is approximately 14.6618%. BLACKROCK INC., holding 6.62 million shares of the stock with an approximate value of $$32.31 million in VERV stocks shares; and BLACKROCK INC., currently with $$25.69 million in VERV stock with ownership which is approximately 6.2492%.
